Is physical activity the forgotten casualty of the GLP-1 revolution?
As GLP-1 receptor agonists become embedded within obesity care, a striking paradox is emerging. We are investing unprecedented energy, resources, and attention into pharmaceutical treatment of obesity at the very moment that one of the most important determinants of long-term health —